Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Exiqon; RXi Pharmaceuticals; and More

Premium

Title: Synthetic Genes and Genetic Constructs

Patent Number: 8,048,670

Filed: Jan. 15, 2004

Lead Inventor: Michael Graham, Commonweath Scientific and Industrial Research Organization (Benitec)

The invention, the patent's abstract states, “relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue, or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the … invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.”


Title: RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions

Patent Number: 8,048,863

Filed: April 13, 2007

Lead Inventor: John Yanni, Alcon

The invention, the patent's abstract states, comprises “RNA interference … for inhibition of spleen tyrosine kinase mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.”


Title: Mediated Cellular Delivery of LNA Oligonucleotides

Patent Number: 8,048,998

Filed: Jan. 18, 2008

Lead Inventor: Soeren Vestergaard Rasmussen, Exiqon

The invention, the patent's abstract states, “relates to novel modified oligomeric compounds and to methods of making and using such compounds. The invention further relates to methods of enhancing the cellular uptake of oligomeric compounds comprising conjugating a metal chelator to those.”


Title: Construction of Protein-Responsive shRNA/RNAi Control System Using RNP Motif

Application Number: 20110263026

Filed: Dec. 9, 2009

Lead Inventor: Tan Inoue, Japan Science and Technology Agency

The invention, the patent application's abstract states, comprises an “RNAi control system using an RNA-protein interaction motif,” as well as an shRNA composed of a guide strand, a passenger strand, and “a linker strand” made up of an RNP-derived protein-binding motif sequence.


Title: Delivery of Agents Using Interfering Nanoparticles

Application Number: 20110263514

Filed: March 16, 2011

Inventor: Tariq Rana, Sanford-Burnham Medical Research Institute

The patent application, its abstract states, claims “compositions and methods for delivery of therapeutic agents, such as chemically stabilized antisense oligonucleotides useful in RNA silencing. The compositions include interfering nanoparticles associated with one or more agents. Several functional iNOP derivatives are provided [that] allow for targeted delivery of agents to specific cell types as well as exhibiting reduced cellular toxicity.”


Title: Small Interfering RNA for Gene Knockdown of the Subcutaneous N-Methyl-D-Aspartate Receptor NR1 Subunit and Its Application of Pharmaceutics

Application Number: 20110263676

Filed: May 14, 2010

Inventor: Ping-Heng Tan, I-Shou University

The invention comprises a “small interfering RNA for gene knockdown of the N-methyl-D-aspartate receptor NR1 subunit,” as well as “a method of … applying the small interfering RNA on subcutaneous tissues [to temporarily] interfere with the genetic expression of the NMDA receptor NR1 subunit in the hypoderm,” the patent application's abstract states.

The siRNA can be used to moderate “inflammatory pain or intolerable chronic pain, especially on clinical chronic pain and burn ... patients,” it adds.


Title: Reduced Size Self-Delivering RNAi Compounds

Application Number: 20110263680

Filed: March 23, 2011

Lead Inventor: Anastasia Khvorova, RXi Pharmaceuticals

The invention relates to “RNAi constructs with minimal double-stranded regions, and their use in gene silencing,” the patent application's abstract states. “RNAi constructs associated with the invention include a double-stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.”


Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid

Application Number: 20110263683

Filed: May 11, 2011

Lead Inventor: Leonid Beigelman, Merck

The invention, the patent application's abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules ... capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.